Rx/Dx（治療薬とコンパニオン診断薬）の開発、商品化、提携のためのモデル Aligning Emerging Models for Rx and Dx with Regulatory and Reimbursement Policies to Improve Patient Care and Stimulate New Drug & Diagnostic Products and Partnerships
Strategies for building diagnostic capabilities to accelerate new product development
Emerging business/economic models for Rx/Dx collaboration or co-development
How to optimize a platform technology for clinical diagnostic use and/or reimbursement potential?
Success factors in Rx/Dx partnering to support commercial launch of a drug
Are current regulatory guidelines appropriate for co-development of therapeutics and diagnostics?
The case for and against Companion Dx test regulation: FDA-Approved vs. lab-developed tests
Reimbursement policies/strategies in the new era of Rx/Dx collaboration: Is there a workable model?
Aligning strategies for drug and diagnostic co-development in early planning and R&D
Where do the opportunities lie for future drug/diagnostic development?
Opportunities and challenges for drug developers
Opportunities and challenges for diagnostic companies and technology platform providers
Opportunities and challenges for payers and healthcare organizations
Opportunities and challenges for physician-scientists and their patients
Case studies of companion diagnostics in development or approved
未来の臨床診断薬 Optimizing Product Development and Commercialization through Clinical Applications of Next-Generation Sequencing and other Lifescience Platform Technologies
New developments in infectious disease diagnostics
New developments in cancer diagnostics
Sequencing applications for clinical diagnostics
Diagnostics for personalizing medicine/clinical treatment at the bedside
Strategies to inform biology-based clinical treatment decisions in patients
New technologies for finding diagnostic biomarkers
Impact of technology changes on clinical diagnostics and hospital practices
Evolving diagnostic technologies: from mass spec , microarrays and PCR to sequencing, hybrid selection techniques and exomes